89 related articles for article (PubMed ID: 7933670)
1. The effect of recombinant human erythropoietin (r-HuEPO) on left ventricular mass and left ventricular hemodynamics in hemodialysis patients.
Minagawa T; Hirano T; Takada N; Ishiguro M; Ohtsuka H
Nihon Jinzo Gakkai Shi; 1994 Aug; 36(8):934-41. PubMed ID: 7933670
[TBL] [Abstract][Full Text] [Related]
2. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
[TBL] [Abstract][Full Text] [Related]
3. Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure.
Morris KP; Skinner JR; Hunter S; Coulthard MG
Arch Dis Child; 1993 May; 68(5):644-8. PubMed ID: 8323333
[TBL] [Abstract][Full Text] [Related]
4. [An echocardiographic study of the left ventricular functional indices in pediatric patients on hemodialysis and in treatment with recombinant human erythropoietin (r-HuEPO)].
Seracini D; Pollini I; Lavoratti GC; Pela I; Materassi M; Danti D; De Simone L; Favilli S; Manetti A
Pediatr Med Chir; 1994; 16(4):389-92. PubMed ID: 7816703
[TBL] [Abstract][Full Text] [Related]
5. The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure.
Singh NP; Chandrashekhar ; Nair M; Anuradha S; Kohli R; Agarwal SK
J Assoc Physicians India; 2000 Mar; 48(3):301-6. PubMed ID: 11229114
[TBL] [Abstract][Full Text] [Related]
6. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
Radermacher J; Koch KM
Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
[TBL] [Abstract][Full Text] [Related]
7. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients.
Lebel M; Kingma I; Grose JH; Langlois S
Am J Hypertens; 1995 Jun; 8(6):545-51. PubMed ID: 7662237
[TBL] [Abstract][Full Text] [Related]
8. Haemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin.
Jurić M; Rupcić V; Topuzović N; Jakić M; Brlosić R; Rusić A; Karner I; Stipanić S; Kes P
Nephrol Dial Transplant; 1995; 10(8):1398-404. PubMed ID: 8538932
[TBL] [Abstract][Full Text] [Related]
9. [Numerical and functional alterations in T and B lymphocyte subpopulations in CAPD patients treated with recombinant human erythropoietin].
Tanabe R
Nihon Jinzo Gakkai Shi; 1994 Oct; 36(10):1159-68. PubMed ID: 7815748
[TBL] [Abstract][Full Text] [Related]
10. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO).
Roger SD; Baker LR; Raine AE
Clin Nephrol; 1993 Feb; 39(2):103-10. PubMed ID: 8448912
[TBL] [Abstract][Full Text] [Related]
11. [The effects of r-HuEPO on platelet function and coagulation factors in hemodialysis patients].
Kinugasa E; Nabeshima K; Niikura K; Kawabe S; Akizawa T; Kitaoka T; Koshikawa S
Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1109-16. PubMed ID: 2287103
[TBL] [Abstract][Full Text] [Related]
12. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
[TBL] [Abstract][Full Text] [Related]
13. [Effects of hemodialysis on left ventricular performance: a Doppler echocardiographic study].
Nitta M; Takamoto T; Yajima T; Adachi H; Tanaka C; Chida Y; Taniguchi K; Marumo F
J Cardiol; 1989 Dec; 19(4):1117-25. PubMed ID: 2535021
[TBL] [Abstract][Full Text] [Related]
14. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
16. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin.
Silberberg J; Racine N; Barre P; Sniderman AD
Can J Cardiol; 1990; 6(1):1-4. PubMed ID: 2138048
[TBL] [Abstract][Full Text] [Related]
17. Systolic function impairment in higher erythropoietin requirement patients in hemodialysis.
Trovato GM; Iannetti E; Carpinteri G
Recenti Prog Med; 1997 May; 88(5):217-22. PubMed ID: 9200965
[TBL] [Abstract][Full Text] [Related]
18. Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO).
Jeren-Struji'c B; Raos V; Jeren T; Horvatin-Godler S
Angiology; 2000 Feb; 51(2):131-9. PubMed ID: 10701721
[TBL] [Abstract][Full Text] [Related]
19. Could CAPD modulate the hemodynamic changes induced by rHuEPO treatment?
Fernández A; Vega N; Hortal L; Jimenez F; Laraudogoitía E; Macía M; Plaza C; Perdomo M; Palop L
Adv Perit Dial; 1992; 8():435-9. PubMed ID: 1361842
[TBL] [Abstract][Full Text] [Related]
20. [The effect of correcting anemia with recombinant erythropoietin on the central hemodynamic indices of patients on regular hemodialysis].
Ermolenko VM; Khvoĭnitskiĭ VA; Suprun EK; Tsukerman LI; Pokrovskiĭ IuA
Ter Arkh; 1992; 64(7):86-8. PubMed ID: 1440377
[No Abstract] [Full Text] [Related]
[Next] [New Search]
